What is a probiotic strain?
To understand why strain designations matter, you need to understand the difference between species and strain. Every bacterium has a hierarchical classification: kingdom, phylum, class, order, family, genus, species, strain. The species name like Lactobacillus rhamnosus tells you the broad biological group. The strain identifier tells you exactly which specific organism within that group you are dealing with.
Think of it like dog breeds. Every Labrador, every Pug, and every Great Dane belongs to the species Canis lupus familiaris. They are all dogs. But their behaviour, size, and temperament are vastly different. You would not buy a Great Dane because you wanted a Pug. Probiotic strains within a species can be just as different from each other.
What strain codes like ATCC 53103 actually mean
Strain identifiers are catalogue numbers maintained by international microbial collections. Each collection assigns a unique number to a specific bacterial isolate, frozen and preserved as a reference culture. When a research paper cites "LGG ATCC 53103" or "S. boulardii CNCM I-745", they are pointing to one specific, traceable organism that any other researcher can request from the collection.
The major culture collections
- ATCC (American Type Culture Collection, USA): the most widely cited collection. ATCC 53103 is the catalogue number for the LGG strain.
- CNCM (Collection Nationale de Cultures de Microorganismes, France): CNCM I-745 is the catalogue number for the S. boulardii strain used in Biocodex products.
- DSM (Deutsche Sammlung von Mikroorganismen, Germany): DSM 17938 is a well-known L. reuteri strain.
- Branded codes: some strain owners use proprietary codes like HOWARU Bl-04 (IFF) or BB-12 (Chr. Hansen).
A strain designation gives you traceability. You can look up "LGG ATCC 53103" on PubMed and find every clinical trial conducted on that exact organism. Without the designation, you are buying a black box.
Why strain specificity matters clinically
Different strains of the same species can have dramatically different effects in the gut. This is not theoretical. It is well-documented in the scientific literature.
Adhesion to the gut lining
LGG ATCC 53103 has surface proteins called SpaCBA pili that allow it to physically grip the intestinal mucus layer. This adhesion is what gives LGG its colonisation advantage. Other Lactobacillus rhamnosus strains may lack these specific pili and pass through the gut without establishing.
Bile and acid tolerance
Some strains survive stomach acid and bile salts well. Others do not. Two strains of the same species, both labelled Lactobacillus rhamnosus, can have completely different survival rates through the gastrointestinal tract. The strain that survives is the one that has clinical effect.
Production of bioactive metabolites
Bacteria produce different short-chain fatty acids, bacteriocins, and immune-modulating compounds depending on their strain. B. lactis Bl-04 produces more acetate. Other B. lactis strains have different metabolic profiles. The clinical effects flow from these specific outputs, not from the species name.
Immune system interaction
Different strains stimulate different immune responses. LGG ATCC 53103 is documented to enhance Th1 immune response and regulatory T-cell activity. Other L. rhamnosus strains may not. Substituting a different strain means substituting a different clinical effect.
The meta-analysis showing LGG reduces antibiotic-associated diarrhoea by 49 percent covers 12 RCTs with 1,499 participants, all using ATCC 53103. That evidence base does not transfer to a generic Lactobacillus rhamnosus product. Yet many pharmacy probiotic labels list "Lactobacillus rhamnosus" without specifying the strain, implicitly borrowing credibility from clinical evidence that does not apply to their product.
What this means for Indian pharmacy probiotics
Walk into any pharmacy in Hyderabad, Bengaluru, or Mumbai and pick up a probiotic. Read the label. In almost every case, you will see species names without strain identifiers: "Lactobacillus acidophilus", "Bifidobacterium longum", "Lactobacillus rhamnosus". No ATCC. No CNCM. No proprietary code.
This is not an accident or a labelling oversight. It indicates that the manufacturer is using unlicensed generic strains. Licensed strains carry licensing fees from the original strain owner. Generic strains can be cultured cheaply by any microbiology lab. Most pharmacy probiotics use the generic route to keep the retail price under Rs. 200.
The result is a product that looks like the clinical literature on the label, but does not actually contain the organism the clinical literature studied. The species name is the same. The strain, and therefore the evidence base, is different.
The strains used in Aegis Protocol
Every probiotic ingredient in Aegis Protocol uses a specific designated strain with its own clinical evidence base.
Lactobacillus rhamnosus GG (LGG)
Over 1,000 published studies and 300 clinical trials specifically on ATCC 53103. The 12-RCT meta-analysis for antibiotic-associated diarrhoea reduction (1,499 participants, 49 percent risk reduction) applies to this strain only. EFSA has approved a health claim specific to ATCC 53103.
Saccharomyces boulardii
The Biocodex-licensed strain CNCM I-745 has 21 RCTs covering antibiotic-associated diarrhoea prevention, showing 53 percent risk reduction versus placebo. WGO Grade A evidence rating. Different S. boulardii strains from other suppliers have different evidence profiles and are not interchangeable.
Bifidobacterium lactis
The IFF (formerly Danisco) HOWARU range strain Bl-04. RCT evidence for maintaining Bifidobacteria levels during and after antibiotic therapy, with benefits persisting two weeks post-treatment. Specifically chosen for its complementary large intestinal niche colonisation alongside LGG's small intestinal coverage.
How to check if your probiotic uses a licensed strain
Three things to look for on the label:
- Strain identifier present: ATCC, CNCM, DSM, or a clear proprietary code (HOWARU, BB-12, etc.) listed next to the species name. If only the species name appears, it is almost certainly a generic strain.
- CFU specification: viable bacterial count specified at end of shelf life, not at manufacturing. End-of-shelf-life declarations are the honest way to label probiotics. At-manufacturing declarations can mean as little as 10 percent of the stated CFU by the time you take the capsule.
- Capsule technology: HPMC delayed release capsules survive stomach acid. Standard gelatin capsules dissolve in gastric acid and destroy 90 percent or more of the probiotic before it reaches the intestine. The capsule format matters as much as the strain.
When you see a probiotic label that lists only species names without strain identifiers, you are looking at a product whose clinical claims cannot be supported by the published evidence. The species name is the same as in the trials. The organism inside is different.
References
- Szajewska H, Kolodziej M (2015), Aliment Pharmacol Ther, PMID 26365389: LGG ATCC 53103 meta-analysis for AAD prevention.
- Szajewska H, Kolodziej M (2015), Aliment Pharmacol Ther: Systematic review of S. boulardii CNCM I-745 for AAD prevention.
- Sanders ME et al. (2018), Nutrients: Probiotic strain specificity in clinical research.
- Hill C et al. (2014), Nat Rev Gastroenterol Hepatol: ISAPP consensus statement on the scope and appropriate use of the term probiotic.